Saskia Koene1, Paul de Laat2, Doorlène H van Tienoven2, Dennis Vriens2, André M Brandt2, Fred C G J Sweep2, Richard J T Rodenburg2, A Rogier T Donders2, Mirian C H Janssen2, Jan A M Smeitink2. 1. From the Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Mitochondrial Disorders (S.K., P.d.L., R.J.T.R., M.C.H.J., J.A.M.S.), and Departments of Laboratory Medicine (D.H.v.T., A.M.B., F.C.G.J.S.), Radiology and Nuclear Medicine (D.V.), Health Evidence (A.R.T.D.), and General Internal Medicine (M.C.H.J.), Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. saskia.koene@radboudumc.nl. 2. From the Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Mitochondrial Disorders (S.K., P.d.L., R.J.T.R., M.C.H.J., J.A.M.S.), and Departments of Laboratory Medicine (D.H.v.T., A.M.B., F.C.G.J.S.), Radiology and Nuclear Medicine (D.V.), Health Evidence (A.R.T.D.), and General Internal Medicine (M.C.H.J.), Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Abstract
OBJECTIVES: To determine the value of fibroblast growth factor 21 (FGF21), a recently discovered biomarker for mitochondrial disease, in predicting clinical disease severity and disease progression in adult carriers of the m.3243A>G mutation. METHODS: In the context of a national inventory, the heteroplasmy levels of the m.3243A>G mutation were measured in leukocytes and urinary epithelial cells. The Newcastle Mitochondrial Disease Adult Scale score was determined and blood was drawn for measuring FGF21 concentration. Twenty-five of the included initial patients studied were then selected randomly for a follow-up study. RESULTS: This prognostic study included 99 adult carriers of the m.3243A>G mutation. Our analysis revealed a moderate, significant correlation between FGF21 concentration and disease severity (r = 0.49; p = <0.001). No significant correlations were found between disease severity and the heteroplasmy percentage determined in urinary epithelial cells or the heteroplasmy percentage determined in leukocytes. Weak but significant correlations were also found between FGF21 concentration and the severity of the myopathy (r = 0.38; p = <0.001) and between the concentration of FGF21 and the severity of the encephalopathy (r = 0.30; p = <0.001). Repeated measurements following 25 subjects for 2 years revealed no significant correlation between FGF21 concentration and disease progression. CONCLUSIONS: Measuring FGF21 concentration had little added value in monitoring and predicting the disease course in this specific patient group.
OBJECTIVES: To determine the value of fibroblast growth factor 21 (FGF21), a recently discovered biomarker for mitochondrial disease, in predicting clinical disease severity and disease progression in adult carriers of the m.3243A>G mutation. METHODS: In the context of a national inventory, the heteroplasmy levels of the m.3243A>G mutation were measured in leukocytes and urinary epithelial cells. The Newcastle Mitochondrial Disease Adult Scale score was determined and blood was drawn for measuring FGF21 concentration. Twenty-five of the included initial patients studied were then selected randomly for a follow-up study. RESULTS: This prognostic study included 99 adult carriers of the m.3243A>G mutation. Our analysis revealed a moderate, significant correlation between FGF21 concentration and disease severity (r = 0.49; p = <0.001). No significant correlations were found between disease severity and the heteroplasmy percentage determined in urinary epithelial cells or the heteroplasmy percentage determined in leukocytes. Weak but significant correlations were also found between FGF21 concentration and the severity of the myopathy (r = 0.38; p = <0.001) and between the concentration of FGF21 and the severity of the encephalopathy (r = 0.30; p = <0.001). Repeated measurements following 25 subjects for 2 years revealed no significant correlation between FGF21 concentration and disease progression. CONCLUSIONS: Measuring FGF21 concentration had little added value in monitoring and predicting the disease course in this specific patient group.
Authors: Saskia Koene; Paul de Laat; Doorlène H van Tienoven; Gert Weijers; Dennis Vriens; Fred C G J Sweep; Janneke Timmermans; Livia Kapusta; Mirian C H Janssen; Jan A M Smeitink Journal: JIMD Rep Date: 2015-05-13
Authors: Jenni M Lehtonen; Saara Forsström; Emanuela Bottani; Carlo Viscomi; Olivier R Baris; Helena Isoniemi; Krister Höckerstedt; Pia Österlund; Mikko Hurme; Juulia Jylhävä; Sirpa Leppä; Ritva Markkula; Tiina Heliö; Giuliana Mombelli; Johanna Uusimaa; Reijo Laaksonen; Hannu Laaksovirta; Mari Auranen; Massimo Zeviani; Jan Smeitink; Rudolf J Wiesner; Kazuto Nakada; Pirjo Isohanni; Anu Suomalainen Journal: Neurology Date: 2016-10-28 Impact factor: 9.910
Authors: S Koene; J Timmermans; G Weijers; P de Laat; C L de Korte; J A M Smeitink; M C H Janssen; L Kapusta Journal: J Inherit Metab Dis Date: 2017-01-04 Impact factor: 4.982
Authors: Ana Peñas; Miguel Fernández-De la Torre; Sara Laine-Menéndez; David Lora; María Illescas; Alberto García-Bartolomé; Montserrat Morales-Conejo; Joaquín Arenas; Miguel A Martín; María Morán; Cristina Domínguez-González; Cristina Ugalde Journal: Int J Mol Sci Date: 2021-06-15 Impact factor: 5.923
Authors: Werner Jh Koopman; Julien Beyrath; Cheuk-Wing Fung; Saskia Koene; Richard J Rodenburg; Peter Hgm Willems; Jan Am Smeitink Journal: EMBO Mol Med Date: 2016-04-01 Impact factor: 12.137